Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | MB | P02144 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.67 |
| ▸ | CA3 | P07451 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | RARG | P13631 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861674 | 0.89 | SMN1; SMN2 (0.84) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL3818831 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL11158565 | 0.82 | MAPT (0.83) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| Acetaminophen SCHEMBL8937727 | 0.80 | KMT2A (1.00) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL4899667 | 0.80 | TDP1 (0.74) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| Acetaminophen SCHEMBL3480 | 0.80 | KMT2A (1.00) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| Acetaminophen SCHEMBL252939 | 0.80 | KMT2A (1.00) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL61417 | 0.80 | TDP1 (1.00) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL1488126 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 | |
| SCHEMBL1808465 | 0.79 | MEN1 (0.58) | SMN1; SMN2L3MBTL1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114890962-B | Synthetic method of 1,2, 4-triazine ring of coccidian-resistant veterinary drug | 山东国邦药业有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114890962-A | Synthetic method of 1,2, 4-triazine ring of coccidian-resistant veterinary drug | 山东国邦药业有限公司 | 2022-08-12 | — | — | CN | claimed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-5352673-A | Administering to inactivate or inhibit phospholipase A | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE A CORP. OF CALIFORNIA | 1994-10-04 | — | — | US | claimed |
| WO-1992022289-A1 | NOVEL PHOSPHOLIPASE A2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-12-23 | — | — | WO | claimed |
| EP-0297855-A1 | Aminocyclopentyl ethers and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1989-01-04 | — | — | EP | claimed |
| EP-0074861-B1 | AMINOCYCLOPENTANE ESTERS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATION | GLAXO GROUP LIMITED (GB) | 1986-08-27 | — | — | EP | claimed |
| EP-0074861-A1 | Aminocyclopentane esters and their preparation and pharmaceutical formulation | GLAXO GROUP LIMITED (GB) | 1983-03-23 | — | — | EP | claimed |
| EP-3421548-B1 | COLORING COMPOSITION, INKJET RECORDING INK, INKJET RECORDING METHOD, AND INKJET PRINTER CARTRIDGE | FUJIFILM CORP (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-114890962-B | Synthetic method of 1,2, 4-triazine ring of coccidian-resistant veterinary drug | 山东国邦药业有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114890962-A | Synthetic method of 1,2, 4-triazine ring of coccidian-resistant veterinary drug | 山东国邦药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-4377688-A | Anthraquinone reactive dyestuffs, their preparation and their use for dyeing materials containing OH groups or amide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1983-03-22 | — | — | US | disclosed |
| US-4268621-A | Direct positive photographic material | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1981-05-19 | — | — | US | disclosed |
| US-4196291-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1980-04-01 | — | — | US | disclosed |
| US-4141978-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-02-27 | — | — | US | disclosed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4001411-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | SMN1; SMN2 2209/4885L3MBTL1 1352/4885HTT 1479/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | SMN1; SMN2 2965/4885L3MBTL1 2998/4885HTT 1692/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | SMN1; SMN2 2928/4885L3MBTL1 1913/4885HTT 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.